相关实验视频

Updated: Jun 21, 2025

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

扎菲尔卢卡斯特诱导DNA凝结,并对复制Mycobacterium疹有杀菌作用

Sanne van der Niet¹, Keith D Green², Irene M Schimmel¹

¹Electron Microscopy Centre Amsterdam, Amsterdam University Medical Centre, Amsterdam, the Netherlands.

Antimicrobial agents and chemotherapy

|July 11, 2024

概括

一种喘药物Zafirlukast在囊性纤维化患者中显示出对Mycobacterium疹感染的潜力. 它破坏了细菌细胞结构并减少了生长,为抗生素研究提供了新的途径.

科学领域:

微生物学微生物学
药物发现药物发现药物发现
传染性疾病传染性疾病

背景情况:

在囊性纤维化患者中,mycobacterium疹感染越来越令人担忧,由于抗生素耐药性,治疗成功有限.
迫切需要新的治疗策略来对抗这些难以治疗的感染.

研究的目的:

调查FDA批准的喘药物扎菲尔卢卡斯特 (zafirlukast) 的潜力,作为治疗Mycobacterium疹感染的新疗法.
评估扎菲尔卢卡斯特对M. abscessus的疗效和作用机制.

主要方法:

最小抑制度 (MIC) 和杀菌度 (MBC) 的确定.
传输电子显微镜 (TEM) 来评估形态变化.
在各种培养介质中进行增长抑制测试.

主要成果:

扎菲尔卢卡斯特抑制了M.的生长,MIC为16μM,在64μM时对复制细菌具有杀菌作用.
治疗诱导了DNA凝结,改变了细菌形态,并破坏了细胞壁的完整性.
TEM揭示了细胞壁的混乱,周等离子体和改变的核糖体.

结论:

扎菲尔卢卡斯特通过改变其形态和细胞结构来表现出对M. abscessus的杀菌活性.
尽管它具有相对较高的杀菌度,但扎菲尔卢卡斯特的FDA批准状况要求对M. abscessus治疗进行进一步的体内调查.

关键词:

这种细菌是Mycobacterium abscessus.抗生素抗生素是一种抗生素.电子显微镜的电子显微镜扎菲尔·卢卡斯特 (扎菲尔·卢卡斯特) 是一个

更多相关视频

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos

Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos

Published on: September 9, 2015

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

相关概念视频

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...